Atturos have successfully completed the Horizon 2020 Phase 1 SME Instrument project “Strategic planning for commercialisation of a multiplexed protein diagnostic (Dx) blood test for Organ-Confined Prostate cancer: OCProDx”. The first iteration of our business plan has been prepared and delivered to the European Commission for review.
This investor-ready business plan details the commercial strategy for the OCProDx test and Atturos. The report is based on information gathered from various activities completed as part of our commercial research. These included the Atturos Brainstorming Sessions, urologist surveys, patent reports, and various other market research activities.
Atturos will continue to build on the work of this project and look forward to collaborating with the EC on future projects.
If you would like to request a copy of our business plan or discuss collaboration projects please use our Contact Form.